Table 1.

Clinical indications of certolizumab pegol

	Present indications	Futures indications
Europe (EMA)	RA	CD, PsO, PsA and SpA
Swiss	RA, CD	PsO, PsA and SpA
Russia	RA, CD	PsO, PsA and SpA
USA	RA, CD	PsO, PsA and SpA
Canada	RA, CD
Chile, Mexico	RA, CD	PsO, PsA and SpA
Argentina	RA, CD
Australia	RA	CD, PsO, PsA and SpA
Asia	RA	CD, PsO, PsA and SpA
Japan	RA

Notes: Cetolizumab pegol was approved for the treatment of rheumatoid arthritis in the EU, US and Canada in 2009, and for the treatment of Crohn’s Disease in Switzerland in 2007 and in the USA in 2008. Certolizumab pegol is entering into an increasingly competitive marketplace, especially in rheumatoid arthritis, but clinical data demonstrate benefits across a range of other inflammatory disease.

Abbreviations: EMA, European Medicines Agency; RA, Rheumatoid Arthritis); CD, Crohn’s disease; PsO, Psoriasis; PsA, Psoriatic Arthritis; SpA Spondyloarthritis.